Regulus Therapeutics Inc.

NasdaqCM:RGLS Stock Report

Market Cap: US$97.6m

Regulus Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Regulus Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-96.1%

Buyback Yield

Total Shareholder Yield-96.1%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Sep 28
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Regulus surges 15% after Phase 1 data for kidney disease candidate

Sep 12

Regulus Therapeutics GAAP loss per share narrows

Aug 11

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Oct 12
Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

The Read On Regulus Therapeutics

Aug 03

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

May 03

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13
Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10
Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Regulus Therapeutics announces closing of $19.4M private placement

Dec 08

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Nov 05

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if RGLS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGLS's dividend payments have been increasing.


Dividend Yield vs Market

Regulus Therapeutics Dividend Yield vs Market
How does RGLS dividend yield compare to the market?
SegmentDividend Yield
Company (RGLS)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.5%
Analyst forecast (RGLS) (up to 3 years)n/a

Notable Dividend: Unable to evaluate RGLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate RGLS's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RGLS has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 11:30
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Regulus Therapeutics Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets U.S. (Historical)
Madhu KumarB. Riley Securities, Inc.